Cofoe Medical (01187) reported solid first-half 2026 results, with revenue climbing 38.5 % year on year to RMB 2.07 billion. Gross profit advanced 51.3 % to RMB 1.13 billion, lifting gross margin by 4.6 percentage points to 54.6 %.

Net profit attributable to shareholders increased 20.8 % to RMB 202.26 million, while total profit for the period rose 21.9 % to RMB 203.20 million. Basic earnings per share reached RMB 0.95 versus RMB 0.82 a year earlier.

Management proposes an interim cash dividend of RMB 0.60 per share (tax inclusive), equivalent to an estimated payout of about RMB 136.28 million. The distribution is subject to shareholder approval and is scheduled for payment by 17 November 2026.

Operating cash flow fell 25.3 % to RMB 262.41 million, reflecting higher inventory and promotional spending. Total assets expanded 12.5 % to RMB 7.46 billion, supported by the May 2026 Hong Kong IPO that raised HK$1.01 billion. Equity attributable to shareholders reached RMB 5.53 billion; the gearing ratio improved slightly to 25.4 %.

Strategically, Cofoe deepened its focus on five core product clusters. Revenue from the top five products grew 50 %, and overseas sales more than doubled to RMB 210 million, extending the company’s footprint to over 60 markets. The group also launched an AI Research Institute, rolled out next-generation devices such as the C11 ventilator, and accelerated digital supply-chain upgrades.

During the period Cofoe repurchased 3.32 million A-shares for RMB 180.99 million under its April 2026 buy-back mandate. A further programme to repurchase up to RMB 200 million worth of A-shares for cancellation was approved in July 2026.

Looking ahead, management will prioritize R&D investment, intelligent manufacturing, omnichannel expansion, and global market penetration while maintaining a disciplined capital structure and dividend commitment.